https://skinoncology.net/news.html UK skin-oncology developments — NICE technology appraisals, NHS England commissioning policies, BAD and RCPath guidelines, key trial publications and WHO classification changes. Curated for UK clinical relevance. en-GB Sat, 06 Jun 2026 13:05:54 +0000 Wed, 20 May 2026 08:44:50 +0000 720 https://skinoncology.net/cscc.html skinoncology-news-pubmed-ncbi-nlm-nih-gov-41546605 Major trial Fri, 01 May 2026 00:00:00 +0000 Foerster Y et al. International journal of dermatology (2026 May). Primary source: https://pubmed.ncbi.nlm.nih.gov/41546605/ Related monograph: https://skinoncology.net/cscc.html https://skinoncology.net/cscc.html skinoncology-news-pubmed-ncbi-nlm-nih-gov-41888635 Major trial Fri, 01 May 2026 00:00:00 +0000 Kato M et al. The Journal of dermatology (2026 May). Primary source: https://pubmed.ncbi.nlm.nih.gov/41888635/ Related monograph: https://skinoncology.net/cscc.html https://skinoncology.net/melanoma.html skinoncology-news-nhs-eng-urn-2426-neoadj-pembro NHS England Wed, 01 Apr 2026 00:00:00 +0000 NHS England URN 2426 commissions three cycles of neoadjuvant pembrolizumab → surgery → adjuvant pembrolizumab for stage III macroscopic resectable cutaneous melanoma in people aged ≥ 12 years. Pathway draws on SWOG S1801 (Patel NEJM 2023), but the NHS England policy is restricted to stage III macroscopic resectable disease. Primary source: https://www.england.nhs.uk/publication/clinical-commissioning-policy-neo-adjuvant-followed-by-adjuvant-pembrolizumab/ Related monograph: https://skinoncology.net/melanoma.html https://skinoncology.net/dfsp.html skinoncology-news-pubmed-ncbi-nlm-nih-gov-41977387 Major trial Wed, 01 Apr 2026 00:00:00 +0000 Bota-Llorca A et al. International journal of molecular sciences (2026 Apr 1). Primary source: https://pubmed.ncbi.nlm.nih.gov/41977387/ Related monograph: https://skinoncology.net/dfsp.html https://skinoncology.net/cscc.html skinoncology-news-pubmed-ncbi-nlm-nih-gov-41145919 Major trial Sun, 01 Mar 2026 00:00:00 +0000 Breukers SE et al. European journal of nuclear medicine and molecular imaging (2026 Mar). Primary source: https://pubmed.ncbi.nlm.nih.gov/41145919/ Related monograph: https://skinoncology.net/cscc.html https://skinoncology.net/bcc.html skinoncology-news-pubmed-ncbi-nlm-nih-gov-41025405 Major trial Sun, 01 Feb 2026 00:00:00 +0000 Doyle CM et al. Head & neck (2026 Feb). Primary source: https://pubmed.ncbi.nlm.nih.gov/41025405/ Related monograph: https://skinoncology.net/bcc.html https://skinoncology.net/uveal-melanoma.html skinoncology-news-nice-ta1027-tebentafusp NICE TA Thu, 09 Jan 2025 00:00:00 +0000 NICE recommends tebentafusp (gp100 × CD3 bispecific T-cell engager) for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. First OS-improving therapy in metastatic uveal melanoma. HLA typing is a prerequisite; CRS and rash are principal toxicities. Primary source: https://www.nice.org.uk/guidance/ta1027 Related monograph: https://skinoncology.net/uveal-melanoma.html https://skinoncology.net/melanoma.html skinoncology-news-swog-s1801-patel-nejm-2023 Major trial Thu, 02 Mar 2023 00:00:00 +0000 Patel et al. NEJM 2023. Three cycles of neoadjuvant pembrolizumab → surgery → adjuvant pembrolizumab significantly improved event-free survival vs surgery + adjuvant pembrolizumab alone in resectable stage III/IV melanoma. NHS England URN 2426 uses this evidence for the narrower stage III macroscopic resectable commissioning policy. Primary source: https://www.nejm.org/doi/10.1056/NEJMoa2211437 Related monograph: https://skinoncology.net/melanoma.html https://skinoncology.net/actinic-keratosis.html skinoncology-news-nice-ta869-tirbanibulin NICE TA Wed, 08 Feb 2023 00:00:00 +0000 Tirbanibulin (microtubule + Src kinase inhibitor) applied once daily for 5 days to face / scalp for non-hyperkeratotic AKs. Short course is the principal advantage over older field agents. Pivotal: KX-01-AK / EXPAQ trials. Primary source: https://www.nice.org.uk/guidance/ta869 Related monograph: https://skinoncology.net/actinic-keratosis.html https://skinoncology.net/melanoma.html skinoncology-news-nice-ta837-adjuvant-pembro-iib NICE TA Wed, 23 Nov 2022 00:00:00 +0000 Adjuvant pembrolizumab for completely resected stage IIB or IIC melanoma in adults and adolescents (≥ 12 years), based on KEYNOTE-716. Toxicity / benefit discussion important in this lower-risk population — risk of irreversible endocrine irAEs. Primary source: https://www.nice.org.uk/guidance/ta837 Related monograph: https://skinoncology.net/melanoma.html https://skinoncology.net/cutaneous-lymphoma.html skinoncology-news-who-haem5-2022 Classification Thu, 22 Sep 2022 00:00:00 +0000 WHO Classification of Haematolymphoid Tumours 5th edition: BPDCN relocated to histiocytic-dendritic neoplasms; primary cutaneous CD4+ small/medium T-cell lymphoma reclassified as lymphoproliferative disorder; ENKTCL drops the “nasal type” qualifier; CD8+ aggressive epidermotropic CTCL listed as provisional. Primary source: https://www.nature.com/articles/s41375-022-01620-2 Related monograph: https://skinoncology.net/cutaneous-lymphoma.html https://skinoncology.net/melanoma.html skinoncology-news-bad-melanoma-2022 BAD Thu, 15 Sep 2022 00:00:00 +0000 Revised margins (≤ 1.0 mm → 1 cm; 1.01–2.0 mm → 1–2 cm with 2 cm preferred where feasible; > 2.0 mm → 2 cm), NG14-aligned SLNB shared-decision wording, and follow-up alignment with NICE NG14 §1.9.15. Primary source: https://onlinelibrary.wiley.com/doi/10.1111/bjd.21885 Related monograph: https://skinoncology.net/melanoma.html https://skinoncology.net/muir-torre.html skinoncology-news-mallorca-2022-lynch Consensus Mon, 01 Aug 2022 00:00:00 +0000 Updated tiered MMR triage algorithm — Tier 1 IHC for MLH1/PMS2/MSH2/MSH6; Tier 2 MLH1-promoter methylation for MLH1/PMS2 loss; Tier 3 referral to genetics for MSH2/MSH6 loss or methylation-negative cases. Sebaceous tumour-specific guidance reduces over-referral of solitary sun-exposed lesions. Primary source: https://www.sciencedirect.com/science/article/pii/S0959804922006505 Related monograph: https://skinoncology.net/muir-torre.html https://skinoncology.net/melanoma.html skinoncology-news-nice-ng14-2022-update NICE NG Wed, 27 Jul 2022 00:00:00 +0000 Updated diagnostic pathway, BRAF analysis, SLNB indications (§1.4.3–4), excision margins (§1.5), stage-specific management, and the §1.9.15 follow-up table that drives the site's follow-up scheduler. Primary source: https://www.nice.org.uk/guidance/ng14 Related monograph: https://skinoncology.net/melanoma.html https://skinoncology.net/cscc.html skinoncology-news-nice-ta802-cemiplimab-cscc NICE TA Wed, 29 Jun 2022 00:00:00 +0000 Cemiplimab (anti-PD-1) for adults with metastatic or locally advanced cSCC not suitable for curative surgery or curative radiotherapy. Replaced the 2019 Cancer Drugs Fund interim guidance (TA592). Pivotal: EMPOWER-CSCC-1. Primary source: https://www.nice.org.uk/guidance/ta802 Related monograph: https://skinoncology.net/cscc.html https://skinoncology.net/neurofibromatosis-1.html skinoncology-news-legius-2021-nf1 Consensus Fri, 30 Apr 2021 00:00:00 +0000 Heterozygous pathogenic NF1 variant identified in normal tissue (≈ 50% VAF) added as a stand-alone diagnostic criterion. Choroidal abnormalities on near-infrared imaging formally added. Clinical criteria retained but better defined. Primary source: https://www.gimjournal.org/article/S1098-3600(21)05242-9/fulltext Related monograph: https://skinoncology.net/neurofibromatosis-1.html https://skinoncology.net/gorlin-syndrome.html skinoncology-news-foulkes-2016-gorlin-surveillance Consensus Tue, 21 Jun 2016 00:00:00 +0000 International Gorlin syndrome surveillance consensus. Gene-stratified paediatric brain MRI: SUFU carriers (medulloblastoma risk ~ 33%) 4-monthly to age 3 then less frequent to age 8; PTCH1 carriers (risk ~ 2%) baseline + less intensive. Radiotherapy avoided. Primary source: https://aacrjournals.org/clincancerres/article/22/13/3215/77968/ Related monograph: https://skinoncology.net/gorlin-syndrome.html